CD34 and stroke disorder: To further evaluate the efficacy of this cell type in human subjects, Chen et al. (2014) conducted a Phase II trial in which autologous PBSCs were mobilized with G-CSF, and 3–8 million sorted CD34+ cells were stereotactically transplanted into 15 chronic stroke patients (stroke onset ranging from 6 months to 5 years prior).